臨床外科78巻12号

2023年11月発行

特集 胃癌に対するconversion surgery—Stage Ⅳでも治したい！ 総論

Conversion surgery—適応とタイミング（術前薬物療法の期間）

著者： 藤谷和正¹ 本告正明¹ 宮崎安弘¹ 広田将司¹

所属機関： ¹大阪急性期・総合医療センター消化器外科

ページ範囲：P.1307 - P.1312

【ポイント】
◆cStage ⅣB胃癌において，標準治療である薬物療法に対するconversion surgeryの全生存期間における優越性を検証したランダム化比較試験の成績は報告されていない．
◆Conversion surgeryの適応としては，欧州におけるOMEC projectでのコンセンサスやランダム化比較試験FLOT5における対象が1つの目安となる．
◆Conversion surgeryを目指した術前薬物療法の適切な施行期間は4〜6か月と推察される．

参考文献

1）Kroese TE, van Laarhoven HWM, Nilsson M, et al：Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment：A systematic review and meta-analysis. Eur J Cancer 166：254-269, 2022

2）Al-Batran SE, Goetze TO, Mueller DW, et al：The RENAISSANCE（AIO-FLOT5）trial：effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase Ⅲ trial of the German AIO/CAO-V/CAOGI. BMC Cancer 17：893, 2017

3）Goetze TO, Al-Batran SE：Perspectives on the management of oligometastatic disease in esophago-gastric cancer. Cancers 14：5200, 2022

4）Sugarbaker TA, Chang D, Koslowe P, et al：Patterns of spread of recurrent intraabdominal sarcoma. Sugarbaker PH（ed）；Peritoneal carcinomatosis：principles of management. Kluwer Academic, Boston, 1996, pp 65-78

5）Ishigami H, Yamaguchi H, Yamashita H, et al：Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings. Gastric Cancer 20：128-134, 2017

6）Kroese TE, van Hillegersberg R, Schoppmann S, et al：Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. Eur J Cancer 164：18-29, 2022

7）Shitara K, Ajani JA, Moehler M, et al：Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature 603：942-948, 2022

8）Kang YK, Chen LT, Ryu MH, et al：Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer（ATTRACTION-4）：a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23：234-247, 2022

9）Boku N, Ryu MH, Kato K, et al：Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer：interim results of a randomized, phase II trial（ATTRACTION-4）. Ann Oncol 30：250-258, 2019

10）van Veldhuisen E, Klompmaker S, Janssen QP, et al：Surgical and oncological outcomes after preoperative FOLFIRINOX chemotherapy in resected pancreatic cancer：an international multicenter cohort study. Ann Surg Oncol 30：1463-1473, 2023

11）Truty MJ, Kendrick ML, Nagorney DM, et al：Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer. Ann Surg 273：341-349, 2021

12）Kroese TE, van Laarhoven HWM, Schoppman SF, et al：Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer：a Delphi consensus study in Europe. Eur J Cancer 185：28-39, 2023

13）ECOG-ACRIN Cancer Research：Testing the addition of radiotherapy to the usual treatment（chemotherapy）for patients with esophageal and gastric cancer that has spread to a limited number of other places in the body. January 30, 2020　https://classic.clinicaltrials.gov/ct2/show/NCT04248452